L3Harris Technologies Inc vs Teladoc Health Inc — how do they compare? L3Harris Technologies Inc trades at $236.97 (market cap $44.12B), while Teladoc Health Inc trades at $5.77 (market cap $1.01B). The key difference: L3Harris Technologies Inc is far larger — about 43.7× Teladoc Health Inc's market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Teladoc Health Inc for 39 Days on average.
| LHX | TDOC | |
|---|---|---|
Market Cap | $44.12B | $1.01B |
Volume | 1,202,852 | 4,668,477 |
Sector | Industrials | Health |
52-Week High | $378.48 | $9.72 |
52-Week Low | $233.63 | $4.47 |
Typical Hold Time | 56 Days | 39 Days |
Enterprise Value | $54.56B | $1.27B |
Dividend Yield | 2.11% | — |
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.92, up 1.41% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 7.34% net income margin. The company secured major defense contracts totaling over $10.7 billion recently, while technical indicators show bearish momentum despite positive analyst sentiment with a $340 consensus price target representing 44% upside potential.
LHX presents a compelling investment case with robust defense contract wins and improving profitability, though investors face headwinds from multiple law firm investigations and bearish technical signals. The stock's current valuation appears reasonable with a P/E of 23.93, but legal uncertainties require careful monitoring alongside the company's strong defense sector positioning.
TDOC trades at $5.54, down 0.36% on the day, with a bearish technical signal and mixed earnings history. The company reported revenue of $2.53B in 2025 but a net loss of $200.32M, reflecting ongoing profitability challenges. Analyst consensus is a 'Hold' with a $8.83 price target, indicating potential upside. Recent news includes a CFO transition and legal investigations, adding to investor uncertainty.
The outlook remains cautious due to persistent losses and competitive pressures, though valuation metrics like P/S of 0.4 and EV/EBITDA of 5.89 suggest the stock is undervalued. Key risks include weak cash flow trends and BetterHelp segment volatility. Upside depends on execution in integrated care and cost management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →